These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16764996)

  • 21. Benign prostatic hyperplasia: a review of its histogenesis and natural history.
    Oesterling JE
    Prostate Suppl; 1996; 6():67-73. PubMed ID: 8630233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Uroflowmetry and its influence factors in benign prostate hyperplasia patients].
    Zhong KB; Jiang XZ; Peng CY
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Feb; 30(1):99-101, 120. PubMed ID: 15871201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deformable phantoms of the prostatic urinary tract for urodynamic investigations.
    Ishii T; Ho CK; Nahas H; Yiu BYS; Chee AJY; Yu ACH
    Med Phys; 2019 Jul; 46(7):3034-3043. PubMed ID: 31049993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of urethral compliance on the steady state p-Q relationships assessed with a mechanical analog of the male lower urinary tract.
    Mijailovich SM; Sullivan MP; Yalla SV; Venegas JG
    Neurourol Urodyn; 2007; 26(2):234-46. PubMed ID: 17039462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Quality of life assessment of the male with benign prostate hypertrophy].
    Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N
    Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ultrastructural studies of the detrusor in patients with benign prostatic hyperplasia].
    Loran OB; Vishnevskiĭ AE; Sekamova SM
    Urol Nefrol (Mosk); 1996; (4):27-31. PubMed ID: 8928345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
    Soulitzis N; Karyotis I; Delakas D; Spandidos DA
    Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for benign prostatic hyperplasia in South Korean men.
    Hong J; Kwon S; Yoon H; Lee H; Lee B; Kim HH; Jeong EK; Park H
    Urol Int; 2006; 76(1):11-9. PubMed ID: 16401915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparisons of urodynamic findings and voiding habits in patients with concomitant benign prostatic hyperplasia and detrusor overactivity presenting with or without the symptom of urgency.
    Tong YC
    Urol Int; 2007; 78(3):219-25. PubMed ID: 17406130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between lower urinary tract symptoms and objective measures of benign prostatic hyperplasia: a Chinese survey.
    Wang JY; Liu M; Zhang YG; Zeng P; Ding Q; Huang J; He DL; Song B; Kong CZ; Pang J
    Chin Med J (Engl); 2008 Oct; 121(20):2042-5. PubMed ID: 19080272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow-up.
    Hamann MF; Naumann CM; Seif C; van der Horst C; Jünemann KP; Braun PM
    Eur Urol; 2008 Oct; 54(4):902-7. PubMed ID: 18502565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
    Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
    Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?].
    Kranjcević K; Marković BB
    Acta Med Croatica; 2007 Feb; 61(1):45-8. PubMed ID: 17593640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pathophysiology of benign prostatic hyperplasia.
    McConnell JD
    J Androl; 1991; 12(6):356-63. PubMed ID: 1722791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Origin and evolution of benign prostatic enlargement.
    McNeal JE
    Invest Urol; 1978 Jan; 15(4):340-5. PubMed ID: 75197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS; Roehrborn CG; Wolford E; Wilson TH
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duct obstruction: the possible etiopathogenesis of benign prostatic hyperplasia.
    Lan R; Ye Z
    Med Hypotheses; 2010 Feb; 74(2):312-3. PubMed ID: 19758767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.